Use of antigen‑primed dendritic cells for inducing antitumor immune responses in vitro in patients with non‑small cell lung cancer

  • Authors:
    • Irina Obleukhova
    • Nataliya Kiryishina
    • Svetlana Falaleeva
    • Julia Lopatnikova
    • Vasiliy Kurilin
    • Vadim Kozlov
    • Aleksander Vitsin
    • Andrey Cherkasov
    • Ekaterina Kulikova
    • Sergey Sennikov
  • View Affiliations

  • Published online on: November 14, 2017     https://doi.org/10.3892/ol.2017.7403
  • Pages:1297-1306
Metrics: HTML 0 views | PDF 0 views
0

Abstract

Cancer is associated with a reduction in immature and mature circulating dendritic cells (DCs), and with an impaired migratory capacity, compared with healthy donors. Therefore, modern approaches to the in vitro generation of DCs loaded with tumor antigens and their use for inducing antitumor immune responses in vivo are being investigated. The purpose of the present study was to investigate the phenotypic and functional characteristics of peripheral blood DC subsets in patients with non‑small cell lung cancer (NSCLC), and the development of an antitumor cytotoxic response by mononuclear cells (MNCs) from patients using in vitro generated antigen‑primed DCs. Heparinized peripheral venous blood samples were obtained from 10 healthy donors and 20 patients with a histologically verified diagnosis of NSCLC. The ability of antigen‑activated DCs to stimulate the activity of MNCs against autologous tumor cells was evaluated using a cytotoxic test. Peripheral blood DC subsets from patients with NSCLC were identified to be decreased and to exhibit an impaired ability to mature, compared with healthy donors. Furthermore, DCs generated from MNCs from patients with NSCLC were able to stimulate a specific cytotoxic response when loaded with autologous tumor lysates or RNA and matured, in vitro. A perforin and granzyme B‑dependent mode of cytotoxicity was primarily induced. The ability of DCs loaded with tumor antigens to increase the cytotoxic activity of MNCs against NSCLC cells in vitro indicates the effective induction and co‑stimulation of T lymphocytes by the generated DCs.

Related Articles

Journal Cover

January 2018
Volume 15 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

2016 Impact Factor: 1.39
Ranked #68/217 Oncology
(total number of cites)

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Obleukhova, I., Kiryishina, N., Falaleeva, S., Lopatnikova, J., Kurilin, V., Kozlov, V. ... Sennikov, S. (2018). Use of antigen‑primed dendritic cells for inducing antitumor immune responses in vitro in patients with non‑small cell lung cancer. Oncology Letters, 15, 1297-1306. https://doi.org/10.3892/ol.2017.7403
MLA
Obleukhova, I., Kiryishina, N., Falaleeva, S., Lopatnikova, J., Kurilin, V., Kozlov, V., Vitsin, A., Cherkasov, A., Kulikova, E., Sennikov, S."Use of antigen‑primed dendritic cells for inducing antitumor immune responses in vitro in patients with non‑small cell lung cancer". Oncology Letters 15.1 (2018): 1297-1306.
Chicago
Obleukhova, I., Kiryishina, N., Falaleeva, S., Lopatnikova, J., Kurilin, V., Kozlov, V., Vitsin, A., Cherkasov, A., Kulikova, E., Sennikov, S."Use of antigen‑primed dendritic cells for inducing antitumor immune responses in vitro in patients with non‑small cell lung cancer". Oncology Letters 15, no. 1 (2018): 1297-1306. https://doi.org/10.3892/ol.2017.7403